PRCT vs. SNN, PEN, STVN, GKOS, BLCO, INSP, NARI, IRTC, NVST, and TMDX
Should you be buying PROCEPT BioRobotics stock or one of its competitors? The main competitors of PROCEPT BioRobotics include Smith & Nephew (SNN), Penumbra (PEN), Stevanato Group (STVN), Glaukos (GKOS), Bausch + Lomb (BLCO), Inspire Medical Systems (INSP), Inari Medical (NARI), iRhythm Technologies (IRTC), Envista (NVST), and TransMedics Group (TMDX). These companies are all part of the "medical equipment" industry.
PROCEPT BioRobotics vs.
Smith & Nephew (NYSE:SNN) and PROCEPT BioRobotics (NASDAQ:PRCT) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, institutional ownership, community ranking, dividends, valuation, analyst recommendations, profitability, media sentiment and risk.
Smith & Nephew has higher revenue and earnings than PROCEPT BioRobotics. PROCEPT BioRobotics is trading at a lower price-to-earnings ratio than Smith & Nephew, indicating that it is currently the more affordable of the two stocks.
In the previous week, PROCEPT BioRobotics had 8 more articles in the media than Smith & Nephew. MarketBeat recorded 15 mentions for PROCEPT BioRobotics and 7 mentions for Smith & Nephew. Smith & Nephew's average media sentiment score of 1.00 beat PROCEPT BioRobotics' score of 0.81 indicating that Smith & Nephew is being referred to more favorably in the media.
25.6% of Smith & Nephew shares are owned by institutional investors. Comparatively, 89.5% of PROCEPT BioRobotics shares are owned by institutional investors. 1.0% of Smith & Nephew shares are owned by insiders. Comparatively, 17.4% of PROCEPT BioRobotics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Smith & Nephew presently has a consensus price target of $27.00, indicating a potential downside of 3.59%. PROCEPT BioRobotics has a consensus price target of $94.29, indicating a potential upside of 54.82%. Given PROCEPT BioRobotics' stronger consensus rating and higher possible upside, analysts plainly believe PROCEPT BioRobotics is more favorable than Smith & Nephew.
Smith & Nephew received 409 more outperform votes than PROCEPT BioRobotics when rated by MarketBeat users. However, 68.97% of users gave PROCEPT BioRobotics an outperform vote while only 54.29% of users gave Smith & Nephew an outperform vote.
Smith & Nephew has a beta of 0.83, meaning that its share price is 17% less volatile than the S&P 500. Comparatively, PROCEPT BioRobotics has a beta of 1.05, meaning that its share price is 5% more volatile than the S&P 500.
Smith & Nephew has a net margin of 0.00% compared to PROCEPT BioRobotics' net margin of -50.07%. Smith & Nephew's return on equity of 0.00% beat PROCEPT BioRobotics' return on equity.
Summary
Smith & Nephew and PROCEPT BioRobotics tied by winning 9 of the 18 factors compared between the two stocks.
Get PROCEPT BioRobotics News Delivered to You Automatically
Sign up to receive the latest news and ratings for PRCT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
PROCEPT BioRobotics Competitors List
Related Companies and Tools
This page (NASDAQ:PRCT) was last updated on 3/25/2025 by MarketBeat.com Staff
Buy PRCT Stock Free PRCT Stock Alerts